345 related articles for article (PubMed ID: 24841238)
1. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
2. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
3. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
[TBL] [Abstract][Full Text] [Related]
4. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
5. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
7. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
Gupta P; Goldenberg DM; Rossi EA; Chang CH
Blood; 2010 Oct; 116(17):3258-67. PubMed ID: 20628151
[TBL] [Abstract][Full Text] [Related]
8. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
9. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
10. Treatment of systemic lupus erythematosus with epratuzumab.
Traczewski P; Rudnicka L
Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
[TBL] [Abstract][Full Text] [Related]
11. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
13. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
[TBL] [Abstract][Full Text] [Related]
14. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
15. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
Tuscano JM; Ma Y; Martin SM; Kato J; O'Donnell RT
Cancer Immunol Immunother; 2011 Jun; 60(6):771-80. PubMed ID: 21347809
[TBL] [Abstract][Full Text] [Related]
16. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
18. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
19. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Goldenberg DM; Rossi EA; Stein R; Cardillo TM; Czuczman MS; Hernandez-Ilizaliturri FJ; Hansen HJ; Chang CH
Blood; 2009 Jan; 113(5):1062-70. PubMed ID: 18941114
[TBL] [Abstract][Full Text] [Related]
20. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
